JP2016503070A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2016503070A5 JP2016503070A5 JP2015551668A JP2015551668A JP2016503070A5 JP 2016503070 A5 JP2016503070 A5 JP 2016503070A5 JP 2015551668 A JP2015551668 A JP 2015551668A JP 2015551668 A JP2015551668 A JP 2015551668A JP 2016503070 A5 JP2016503070 A5 JP 2016503070A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- beta
- composition according
- beta cells
- cells
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
- 239000008194 pharmaceutical composition Substances 0.000 claims 14
- 210000000227 basophil cell of anterior lobe of hypophysis Anatomy 0.000 claims 10
- 108009000020 Glucose Homeostasis Proteins 0.000 claims 5
- 239000003795 chemical substances by application Substances 0.000 claims 5
- 230000014101 glucose homeostasis Effects 0.000 claims 5
- 206010022114 Injury Diseases 0.000 claims 4
- 229960005486 vaccines Drugs 0.000 claims 4
- 230000001172 regenerating Effects 0.000 claims 3
- PMATZTZNYRCHOR-CGLBZJNRSA-N (3S,6S,9S,12R,15S,18S,21S,24S,30S,33S)-30-ethyl-33-[(E,1R,2R)-1-hydroxy-2-methylhex-4-enyl]-1,4,7,10,12,15,19,25,28-nonamethyl-6,9,18,24-tetrakis(2-methylpropyl)-3,21-di(propan-2-yl)-1,4,7,10,13,16,19,22,25,28,31-undecazacyclotritriacontane-2,5,8,11,14,17 Chemical group CC[C@@H]1NC(=O)[C@H]([C@H](O)[C@H](C)C\C=C\C)N(C)C(=O)[C@H](C(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](CC(C)C)N(C)C(=O)[C@@H](C)NC(=O)[C@H](C)NC(=O)[C@H](CC(C)C)N(C)C(=O)[C@H](C(C)C)NC(=O)[C@H](CC(C)C)N(C)C(=O)CN(C)C1=O PMATZTZNYRCHOR-CGLBZJNRSA-N 0.000 claims 2
- 229940119017 Cyclosporine Drugs 0.000 claims 2
- 108010036949 Cyclosporine Proteins 0.000 claims 2
- 206010018429 Glucose tolerance impaired Diseases 0.000 claims 2
- 208000001280 Prediabetic State Diseases 0.000 claims 2
- 229940087463 Proleukin Drugs 0.000 claims 2
- 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims 2
- 208000001072 Type 2 Diabetes Mellitus Diseases 0.000 claims 2
- 229960001265 ciclosporin Drugs 0.000 claims 2
- 230000001771 impaired Effects 0.000 claims 2
- 201000009104 prediabetes syndrome Diseases 0.000 claims 2
- 230000003482 proton pump inhibitor Effects 0.000 claims 2
- 239000000612 proton pump inhibitor Substances 0.000 claims 2
- 210000003289 regulatory T cell Anatomy 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- HMLGSIZOMSVISS-ONJSNURVSA-N (7R)-7-[[(2Z)-2-(2-amino-1,3-thiazol-4-yl)-2-(2,2-dimethylpropanoyloxymethoxyimino)acetyl]amino]-3-ethenyl-8-oxo-5-thia-1-azabicyclo[4.2.0]oct-2-ene-2-carboxylic acid Chemical compound N([C@@H]1C(N2C(=C(C=C)CSC21)C(O)=O)=O)C(=O)\C(=N/OCOC(=O)C(C)(C)C)C1=CSC(N)=N1 HMLGSIZOMSVISS-ONJSNURVSA-N 0.000 claims 1
- RTGDFNSFWBGLEC-SYZQJQIISA-N 2-(morpholin-4-yl)ethyl (4E)-6-(4-hydroxy-6-methoxy-7-methyl-3-oxo-1,3-dihydro-2-benzofuran-5-yl)-4-methylhex-4-enoate Chemical compound COC1=C(C)C=2COC(=O)C=2C(O)=C1C\C=C(/C)CCC(=O)OCCN1CCOCC1 RTGDFNSFWBGLEC-SYZQJQIISA-N 0.000 claims 1
- 108010090726 Alefacept Proteins 0.000 claims 1
- 206010012601 Diabetes mellitus Diseases 0.000 claims 1
- 108010008165 Etanercept Proteins 0.000 claims 1
- 102000008214 Glutamate decarboxylases Human genes 0.000 claims 1
- 108091022086 Glutamate decarboxylases Proteins 0.000 claims 1
- 210000002767 Hepatic Artery Anatomy 0.000 claims 1
- 101700082799 IL2RA Proteins 0.000 claims 1
- 102100002950 ISG20 Human genes 0.000 claims 1
- 101700015336 ISG20 Proteins 0.000 claims 1
- 206010022489 Insulin resistance Diseases 0.000 claims 1
- 102000014150 Interferons Human genes 0.000 claims 1
- 108010050904 Interferons Proteins 0.000 claims 1
- 108010023402 Interleukin 1 Receptor Antagonist Protein Proteins 0.000 claims 1
- 102000016664 Interleukin-1 receptor antagonist Human genes 0.000 claims 1
- 210000004153 Islets of Langerhans Anatomy 0.000 claims 1
- 102100009073 LAD1 Human genes 0.000 claims 1
- 101700072115 LAD1 Proteins 0.000 claims 1
- 208000001921 Latent Autoimmune Diabetes in Adults Diseases 0.000 claims 1
- 210000004185 Liver Anatomy 0.000 claims 1
- 210000000496 Pancreas Anatomy 0.000 claims 1
- 210000003240 Portal Vein Anatomy 0.000 claims 1
- 208000008425 Protein Deficiency Diseases 0.000 claims 1
- 108010001645 Rituximab Proteins 0.000 claims 1
- 101710009148 SERPINA1 Proteins 0.000 claims 1
- QFJCIRLUMZQUOT-HPLJOQBZSA-N Sirolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1C[C@@H](C)[C@H]1OC(=O)[C@@H]2CCCCN2C(=O)C(=O)[C@](O)(O2)[C@H](C)CC[C@H]2C[C@H](OC)/C(C)=C/C=C/C=C/[C@@H](C)C[C@@H](C)C(=O)[C@H](OC)[C@H](O)/C(C)=C/[C@@H](C)C(=O)C1 QFJCIRLUMZQUOT-HPLJOQBZSA-N 0.000 claims 1
- 229960001967 Tacrolimus Drugs 0.000 claims 1
- QJJXYPPXXYFBGM-LFZNUXCKSA-N Tacrolimus Chemical compound C1C[C@@H](O)[C@H](OC)C[C@@H]1\C=C(/C)[C@@H]1[C@H](C)[C@@H](O)CC(=O)[C@H](CC=C)/C=C(C)/C[C@H](C)C[C@H](OC)[C@H]([C@H](C[C@H]2C)OC)O[C@@]2(O)C(=O)C(=O)N2CCCC[C@H]2C(=O)O1 QJJXYPPXXYFBGM-LFZNUXCKSA-N 0.000 claims 1
- 210000003606 Umbilical Veins Anatomy 0.000 claims 1
- 229940046008 Vitamin D Drugs 0.000 claims 1
- 229930003316 Vitamin D Natural products 0.000 claims 1
- 229960002459 alefacept Drugs 0.000 claims 1
- 229960004238 anakinra Drugs 0.000 claims 1
- 230000001494 anti-thymocyte Effects 0.000 claims 1
- 230000001475 anti-trypsic Effects 0.000 claims 1
- 239000000427 antigen Substances 0.000 claims 1
- 102000038129 antigens Human genes 0.000 claims 1
- 108091007172 antigens Proteins 0.000 claims 1
- 230000015572 biosynthetic process Effects 0.000 claims 1
- 229960000403 etanercept Drugs 0.000 claims 1
- 238000005755 formation reaction Methods 0.000 claims 1
- 230000004153 glucose metabolism Effects 0.000 claims 1
- 229940079322 interferon Drugs 0.000 claims 1
- 239000003407 interleukin 1 receptor blocking agent Substances 0.000 claims 1
- 238000001361 intraarterial administration Methods 0.000 claims 1
- 238000001990 intravenous administration Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
- 229960004866 mycophenolate mofetil Drugs 0.000 claims 1
- 210000004923 pancreatic tissues Anatomy 0.000 claims 1
- 239000000816 peptidomimetic Substances 0.000 claims 1
- 229920000333 poly(propyleneimine) Polymers 0.000 claims 1
- 230000002062 proliferating Effects 0.000 claims 1
- 229960004641 rituximab Drugs 0.000 claims 1
- 229960002930 sirolimus Drugs 0.000 claims 1
- 230000004936 stimulating Effects 0.000 claims 1
- 238000007920 subcutaneous administration Methods 0.000 claims 1
- 239000000126 substance Substances 0.000 claims 1
- 239000002753 trypsin inhibitor Substances 0.000 claims 1
- 201000008827 tuberculosis Diseases 0.000 claims 1
- 235000019166 vitamin D Nutrition 0.000 claims 1
- 239000011710 vitamin D Substances 0.000 claims 1
- 150000003710 vitamin D derivatives Chemical class 0.000 claims 1
Claims (14)
エクスビボでの培養物である膵臓島外管組織のプロトンポンプ阻害剤への接触によって得られたベータ細胞を含み、前記プロトンポンプ阻害剤の量が、前記膵臓島外管組織からベータ細胞を形成するのに有効量である医薬組成物。 A pharmaceutical composition for the treatment of symptoms associated with impaired glucose homeostasis,
Including beta cells obtained by contacting the ex vivo pancreatic islet culture tissue with a proton pump inhibitor, wherein the amount of the proton pump inhibitor forms beta cells from the exocrine pancreatic tissue A pharmaceutical composition in an effective amount.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201361749197P | 2013-01-04 | 2013-01-04 | |
| US61/749,197 | 2013-01-04 | ||
| PCT/US2013/061972 WO2014052625A1 (en) | 2012-09-27 | 2013-09-26 | Insulin independence among patients with diabetes utilizing a ppi in combination with an immune tolerance agent |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2016503070A JP2016503070A (en) | 2016-02-01 |
| JP2016503070A5 true JP2016503070A5 (en) | 2016-11-10 |
Family
ID=54250581
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015551668A Pending JP2016503070A (en) | 2013-01-04 | 2013-09-26 | Insulin independence among patients with diabetes utilizing PPI in combination with tolerogenic agents |
Country Status (2)
| Country | Link |
|---|---|
| EP (1) | EP2941250A4 (en) |
| JP (1) | JP2016503070A (en) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8732150B2 (en) | 2010-09-23 | 2014-05-20 | Salesforce.Com, Inc. | Methods and apparatus for suppressing network feed activities using an information feed in an on-demand database service environment |
| US20140280577A1 (en) | 2013-03-15 | 2014-09-18 | Salesforce.Com, Inc. | Systems and methods for interacting with an application in a publisher |
| US9665261B2 (en) | 2013-10-28 | 2017-05-30 | Salesforce.Com, Inc. | Providing a user interface for customizing state transitions of panes in a bounding window |
| US10198484B2 (en) | 2015-09-10 | 2019-02-05 | Salesforce.Com, Inc. | Displaying reduced and detailed visual representations of calendar items based on mouse cursor movement |
| JP2019077615A (en) * | 2016-03-09 | 2019-05-23 | 公立大学法人和歌山県立医科大学 | Therapeutic agents for non-alcoholic fatty liver diseases/non-alcoholic steatohepatitis |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2609667C (en) * | 2005-05-25 | 2011-02-22 | Curedm, Inc. | Human proislet peptide, derivatives and analogs thereof, and methods of using same |
-
2013
- 2013-09-26 JP JP2015551668A patent/JP2016503070A/en active Pending
- 2013-09-26 EP EP13840277.1A patent/EP2941250A4/en not_active Withdrawn
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| Guggilam et al. | TNF-α blockade decreases oxidative stress in the paraventricular nucleus and attenuates sympathoexcitation in heart failure rats | |
| ES2653615T3 (en) | Plurality of recombinant LAG-3 dose for use in eliciting an immune response from monocytes | |
| JP2016503070A5 (en) | ||
| HRP20170056T2 (en) | Low frequency glatiramer acetate therapy | |
| JP2020033360A5 (en) | ||
| EA201270167A1 (en) | DOSAGE FORM OF GLETIRAMER ACETATE WITH A REDUCED VOLUME AND METHODS OF INTRODUCTION | |
| JP2012067116A5 (en) | ||
| Barbeau et al. | Double-blind evaluation of oral L-prolyl-Lleucyl-glycine amide in Parkinson's disease. | |
| Kholdani et al. | Macitentan for the treatment of pulmonary arterial hypertension | |
| US20230255931A1 (en) | Pharmaceutical compositions useful for the treatment of tissue injury | |
| Lowe et al. | Repeat courses of intravenous alefacept in patients with chronic plaque psoriasis provide consistent safety and efficacy | |
| Edmonds et al. | Influence of commonly used pharmaceutical agents on equine bone marrow‐derived mesenchymal stem cell viability | |
| KR102205368B1 (en) | New therapies for FXR agonists | |
| AR068229A1 (en) | COMPOSITIONS AND METHODS TO TREAT IMMUNOLOGICAL AND INFLAMMATORY DISEASES AND DISORDERS | |
| CN105358678A (en) | Methods and compositions for the treatment and/or prevention of type 1 diabetes | |
| WO2012044783A8 (en) | Method of achieving a thymosin beta 4 concentration in a human patient | |
| JP2016503070A (en) | Insulin independence among patients with diabetes utilizing PPI in combination with tolerogenic agents | |
| Ma et al. | Immunosuppressive effect of compound K on islet transplantation in an STZ-induced diabetic mouse model | |
| Wu et al. | Steroid-resistant acute rejection after cadaveric liver transplantation: Experience from one single center | |
| Jeon et al. | Rhabdomyolysis associated with single-dose intravenous esomeprazole administration: A case report | |
| WO2013104928A1 (en) | Peptide and uses thereof | |
| Lobritto et al. | Pharmacokinetics of mycophenolate mofetil in stable pediatric liver transplant recipients receiving mycophenolate mofetil and cyclosporine | |
| WO2019229525A2 (en) | TREATMENT OF SKIN DISEASES OR DISORDERS BY DELIVERY OF ANTI-OSMRβ ANTIBODY | |
| Colombo et al. | Clinical profile of cyclosporine in dermatology | |
| RU2337684C1 (en) | Method of treatment of advanced neurosyphilis |